Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Rooks

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of the American Geriatrics Society|November 18, 2017
Reply to: New Hope for SarcopeniaDaniel Rooks, Ronenn Roubenoff
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 4, 2023
Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic DysfunctionSe-Jin Lee, Shalender Bhasin, Lloyd Klickstein, et al.
Journal of Cachexia, Sarcopenia and Muscle|December 2, 2020
Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohortDaniel Rooks, Olivier Petricoul, Jens Praestgaard, et al.
Frontiers in Physiology|September 30, 2024
The therapeutic potential of exercise for improving mobility in multiple sclerosisGiuseppe Locatelli, Martin Stangel, Daniel Rooks, et al.
Journal of the American Geriatrics Society|June 28, 2017
Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept StudyDaniel Rooks, Jens Praestgaard, Sam Hariry, et al.
Clinical Endocrinology|March 23, 2018
Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axesTania Garito, Marjorie Zakaria, Dimitris A Papanicolaou, et al.
Clinical Pharmacokinetics|December 17, 2022
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)Olivier Petricoul, Arman Nazarian, Uwe Schuehly, et al.
The Journal of Clinical Endocrinology and Metabolism|March 24, 2026
Cardiac Safety of Chronic Inhibition of the Myostatin-Activin Pathway with Bimagrumab in Healthy Older AdultsDaniel Rooks, Denise P Yates, Srikanth Neelakantham, et al.
Diabetes, Obesity & Metabolism|June 24, 2017
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individualsTania Garito, Ronenn Roubenoff, Marcus Hompesch, et al.
Therapeutic Innovation & Regulatory Science|May 10, 2018
Developing and Implementing Performance Outcome Assessments: Evidentiary, Methodologic, and Operational ConsiderationsElizabeth Richardson, Jessica Burnell, Heather R Adams, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of the American Geriatrics Society|November 18, 2017
Reply to: New Hope for SarcopeniaDaniel Rooks, Ronenn Roubenoff
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 4, 2023
Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic DysfunctionSe-Jin Lee, Shalender Bhasin, Lloyd Klickstein, et al.
Journal of Cachexia, Sarcopenia and Muscle|December 2, 2020
Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohortDaniel Rooks, Olivier Petricoul, Jens Praestgaard, et al.
Frontiers in Physiology|September 30, 2024
The therapeutic potential of exercise for improving mobility in multiple sclerosisGiuseppe Locatelli, Martin Stangel, Daniel Rooks, et al.
Journal of the American Geriatrics Society|June 28, 2017
Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept StudyDaniel Rooks, Jens Praestgaard, Sam Hariry, et al.
Clinical Endocrinology|March 23, 2018
Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axesTania Garito, Marjorie Zakaria, Dimitris A Papanicolaou, et al.
Clinical Pharmacokinetics|December 17, 2022
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)Olivier Petricoul, Arman Nazarian, Uwe Schuehly, et al.
The Journal of Clinical Endocrinology and Metabolism|March 24, 2026
Cardiac Safety of Chronic Inhibition of the Myostatin-Activin Pathway with Bimagrumab in Healthy Older AdultsDaniel Rooks, Denise P Yates, Srikanth Neelakantham, et al.
Diabetes, Obesity & Metabolism|June 24, 2017
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individualsTania Garito, Ronenn Roubenoff, Marcus Hompesch, et al.
Therapeutic Innovation & Regulatory Science|May 10, 2018
Developing and Implementing Performance Outcome Assessments: Evidentiary, Methodologic, and Operational ConsiderationsElizabeth Richardson, Jessica Burnell, Heather R Adams, et al.
Pageof 2